Nat. Biotechnol. 25, 1256–1264 (2007); published online 7 November 2007; corrected after print 7 December 2007
In the version of this article initially published, on p. 1258, paragraph 2, the incorrect serum concentrations to reach steady state and the incorrect accumulation ratio (Racc) for eculizumab were given. The corrected sentence reads “Eculizumab serum concentrations appear to reach steady state after ∼57 days. At steady state, the eculizumab accumulation ratio (Racc) was calculated to be 1.075.” In addition, in Figure 5, in the PDF version only, the word “assessment” was cut off the bottom of the box beginning “September 2006.” The final sentence should read “BLA and MAA submitted to FDA and EMEA, respectively; receive accelerated assessment.” And in Table 1, the heading “Units of packed RBCs transfused/patient/month” now appears in a separate row. The errors have been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt1344
Rights and permissions
About this article
Cite this article
Rother, R., Rollins, S., Mojcik, C. et al. Erratum: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25, 1488 (2007). https://doi.org/10.1038/nbt1207-1488c
Issue Date:
DOI: https://doi.org/10.1038/nbt1207-1488c